Mechanism of amylin fibrillization enhancement by heparin.
about
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitusMechanisms of islet amyloidosis toxicity in type 2 diabetesOn the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP PeptidesHeparin acts as a structural component of β-endorphin amyloid fibrils rather than a simple aggregation promoter.Effects of Protein Corona on IAPP Amyloid Aggregation, Fibril Remodelling, and CytotoxicityAmide proton solvent protection in amylin fibrils probed by quenched hydrogen exchange NMR.Type 2 diabetes as a protein misfolding disease.Antimicrobial activity of iron oxide nanoparticle upon modulation of nanoparticle-bacteria interface.Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology.Amyloid formation in heterogeneous environments: islet amyloid polypeptide glycosaminoglycan interactionsIslet amyloid: from fundamental biophysics to mechanisms of cytotoxicity.Aggregation of islet amyloid polypeptide: from physical chemistry to cell biology.Mechanistic Contributions of Biological Cofactors in Islet Amyloid Polypeptide Amyloidogenesis.The role of copper(II) in the aggregation of human amylin.Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance.New insights into the roles of sulfated glycosaminoglycans in islet amyloid polypeptide amyloidogenesis and cytotoxicity.The ability of insulin to inhibit the formation of amyloid by pro-islet amyloid polypeptide processing intermediates is significantly reduced in the presence of sulfated glycosaminoglycans.Sulfated glycosaminoglycans in protein aggregation diseases.Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.Molecular Origins of the Compatibility between Glycosaminoglycans and Aβ40 Amyloid FibrilsCharge-Based Inhibitors of Amylin Fibrillization and Toxicity.Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.The role of copper(II) and zinc(II) in the degradation of human and murine IAPP by insulin-degrading enzyme.Peptide Conjugates of Benzene Carboxylic Acids as Agonists and Antagonists of Amylin Aggregation.Aqueous RAFT Synthesis of Glycopolymers for Determination of Saccharide Structure and Concentration Effects on Amyloid β Aggregation.Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I.Insights into the Origin of Distinct Medin Fibril Morphologies Induced by Incubation Conditions and Seeding.Epigallocatechin-3-gallate remodels apolipoprotein A-I amyloid fibrils into soluble oligomers in the presence of heparinModulation of human IAPP fibrillation: cosolutes, crowders and chaperonesGlycosaminoglycan-Protein Interactions by Nuclear Magnetic Resonance (NMR) Spectroscopy
P2860
Q26775893-A85145BE-1D53-4716-907F-C21233442706Q26823708-1D0E49A1-E510-4FEE-BB48-695E184262FDQ27022467-FE4903E3-6ECC-413A-8081-F79B9A178972Q33701765-90A3B50C-47E6-4F88-A9A1-33DAB568361BQ33732704-1088E43E-8830-4B72-8F28-3A8743C98FF1Q34606842-A2E5D012-532F-4E53-8B50-B4C585794EC7Q35822682-9CEFBFC1-C0C9-4CB1-9640-30FAB3C80346Q36123699-93C3AFD8-3748-40A9-A54C-760C0B6AF795Q36327915-CC04A7C8-6B2A-4F08-B3F0-1B08543C480DQ37120788-0985713A-209B-48D9-B816-A80B81537922Q37120813-A20C5A47-E45D-4752-AFD6-FB1735AD87E3Q37672295-A6B5C3BC-676A-40DD-AAEE-F92A4E18994CQ38635739-02B2BFC1-BB7B-4038-BEC8-17ACBF65CEF8Q38969830-7106A488-28F3-4751-83ED-7DCFA89F600DQ39126169-AF699627-1D40-41E5-BFDA-F7329D43D810Q39176222-605274C2-5CE0-4E6D-A093-96C8E6DA395BQ39234687-99987947-1C29-40C0-A04C-4782B5FAE04EQ39236820-0F9887CB-F6F5-4F64-AAE3-5EA298E1BDFDQ39385143-48219AEC-5CF8-468B-A3D0-5A7AA8235EF1Q41301732-699CE044-C656-406B-8E50-59197D045603Q42149035-B39EB5C6-C72A-4D8F-A5A3-3F0B3CB4BEE7Q42255087-FA5764A6-53EE-448A-95DD-94191E2577BDQ42706060-FC1EFA19-1E54-4DE5-99CB-0E1A4322BA0CQ46434649-530BA5E8-6B82-4744-87DC-2939E552E277Q47110220-DD6D03CA-23CB-462B-9813-BEA324BA24B7Q51478393-1264C292-6F0A-4B0A-A7A0-1D7CB00D2DF4Q55213472-B712D2C2-7AAC-4FFC-97E8-ACB05568B195Q56422855-D0BA581E-5DBE-4AB2-A0AC-ABE528F62FE4Q57587073-2AC38B0F-D75D-4645-8948-883D11B75E70Q58696388-DD43517B-2D16-4255-845F-D4CD63577D12
P2860
Mechanism of amylin fibrillization enhancement by heparin.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mechanism of amylin fibrillization enhancement by heparin.
@ast
Mechanism of amylin fibrillization enhancement by heparin.
@en
type
label
Mechanism of amylin fibrillization enhancement by heparin.
@ast
Mechanism of amylin fibrillization enhancement by heparin.
@en
prefLabel
Mechanism of amylin fibrillization enhancement by heparin.
@ast
Mechanism of amylin fibrillization enhancement by heparin.
@en
P2093
P2860
P356
P1476
Mechanism of amylin fibrillization enhancement by heparin
@en
P2093
Andrei T Alexandrescu
Craig E Nelson
Jason Gibson
Nathan N Alder
Sharadrao M Patil
P2860
P304
22894-22904
P356
10.1074/JBC.M110.215814
P407
P50
P577
2011-05-09T00:00:00Z